A Molecular Mechanism for Eflornithine Resistance in African Trypanosomes
Human African trypanosomiasis, endemic to sub-Saharan Africa, is invariably fatal if untreated. Its causative agent is the protozoan parasite Trypanosoma brucei. Eflornithine is used as a first line treatment for human African trypanosomiasis, but there is a risk that resistance could thwart its use, even when used in combination therapy with nifurtimox. Eflornithine resistant trypanosomes were selected in vitro and subjected to biochemical and genetic analysis. The resistance phenotype was verified in vivo. Here we report the molecular basis of resistance. While the drug's target, ornithine decarboxylase, was unaltered in resistant cells and changes to levels of metabolites in the targeted polyamine pathway were not apparent, the accumulation of eflornithine was shown to be diminished in resistant lines. An amino acid transporter gene, TbAAT6 (Tb927.8.5450), was found to be deleted in two lines independently selected for resistance. Ablating expression of this gene in wildtype cells using RNA interference led to acquisition of resistance while expression of an ectopic copy of the gene introduced into the resistant deletion lines restored sensitivity, confirming the role of TbAAT6 in eflornithine action. Eflornithine resistance is easy to select through loss of a putative amino acid transporter, TbAAT6. The loss of this transporter will be easily identified in the field using a simple PCR test, enabling more appropriate chemotherapy to be administered.
Vyšlo v časopise:
A Molecular Mechanism for Eflornithine Resistance in African Trypanosomes. PLoS Pathog 6(11): e32767. doi:10.1371/journal.ppat.1001204
Kategorie:
Research Article
prolekare.web.journal.doi_sk:
https://doi.org/10.1371/journal.ppat.1001204
Souhrn
Human African trypanosomiasis, endemic to sub-Saharan Africa, is invariably fatal if untreated. Its causative agent is the protozoan parasite Trypanosoma brucei. Eflornithine is used as a first line treatment for human African trypanosomiasis, but there is a risk that resistance could thwart its use, even when used in combination therapy with nifurtimox. Eflornithine resistant trypanosomes were selected in vitro and subjected to biochemical and genetic analysis. The resistance phenotype was verified in vivo. Here we report the molecular basis of resistance. While the drug's target, ornithine decarboxylase, was unaltered in resistant cells and changes to levels of metabolites in the targeted polyamine pathway were not apparent, the accumulation of eflornithine was shown to be diminished in resistant lines. An amino acid transporter gene, TbAAT6 (Tb927.8.5450), was found to be deleted in two lines independently selected for resistance. Ablating expression of this gene in wildtype cells using RNA interference led to acquisition of resistance while expression of an ectopic copy of the gene introduced into the resistant deletion lines restored sensitivity, confirming the role of TbAAT6 in eflornithine action. Eflornithine resistance is easy to select through loss of a putative amino acid transporter, TbAAT6. The loss of this transporter will be easily identified in the field using a simple PCR test, enabling more appropriate chemotherapy to be administered.
Zdroje
1. BrunR
BlumJ
ChappuisF
BurriC
2010 Human African trypanosomiasis. Lancet 375 148 159
2. BarrettMP
BoykinDW
BrunR
TidwellRR
2007 Human African trypanosomiasis: pharmacological re-engagement with a neglected disease. British Jounal of Pharmacology 152 1155 1171
3. PriottoG
KasparianS
MutomboW
NgouamaD
GhorashianS
2009 Nifurtimox-eflornithine combination therapy for second-stage African Trypanosoma brucei gambiense trypanosomiasis: a multicentre, randomised, phase III, non-inferiority trial. Lancet 374 56 64
4. OpigoJ
WoodrowC
2009 NECT trial: more than a small victory over sleeping sickness. Lancet 374 7 9
5. BacchiCJ
GarofaloJ
MockenhauptD
McCannPP
DiekemaKA
1983 In vivo effects of alpha-DL-difluoromethylornithine on the metabolism and morphology of Trypanosoma brucei brucei. Molecular and Biochemical Parasitology 7 209 225
6. PhillipsMA
CoffinoP
WangCC
1987 Cloning and sequencing of the ornithine decarboxylase gene from Trypanosoma brucei - implications for enzyme turnover and selective difluoromethylornithine inhibition. Journal of Biological Chemistry 262 8721 8727
7. FairlambAH
HendersonGB
BacchiCJ
CeramiA
1987 In vivo effects of difluoromethylornithine on trypanothione and polyamine levels in bloodstream forms of Trypanosoma brucei. Molecular and Biochemical Parasitology 24 185 191
8. YarlettN
BacchiCJ
1988 Effect of dl-alpha-difluoromethylornithine on methionine cycle intermediates in Trypanosoma brucei brucei. Molecular and Biochemical Parasitology 27 1 10
9. XiaoY
McCloskeyDE
PhillipsMA
2009 RNA interference-mediated silencing of ornithine decarboxylase and spermidine synthase genes in Trypanosoma brucei provides insight into regulation of polyamine biosynthesis. Eukaryotic Cell 8 747 755
10. BitontiAJ
BacchiCJ
McCannPP
SjoerdsmaA
1986 Uptake of alpha-difluoromethylornithine by Trypanosoma brucei brucei. Biochemical Pharmacology 35 351 354
11. PhillipsMA
WangCC
1987 A Trypanosoma brucei mutant resistant to alpha-difluoromethylornithine. Molecular and Biochemical Parasitology 22 9 17
12. BellofattoV
FairlambAH
HendersonGB
CrossGA
1987 Biochemical changes associated with alpha-difluoromethylornithine uptake and resistance in Trypanosoma brucei. Molecular and Biochemical Parasitology 25 227 238
13. CarterNS
FairlambAH
1993 Arsenical resistant trypanosomes lack an unusual adenosine transporter. Nature 361 173 176
14. StewartML
KrishnaS
BurchmoreRJ
BrunR
De KoningHP
2005 Detection of arsenical drug resistance in Trypanosoma brucei with a simple fluorescence test. Lancet 366 486 487
15. MatovuE
GeiserF
SchneiderV
MaserP
EnyaruJC
2001 Genetic variants of the TbAT1 adenosine transporter from African trypanosomes in relapse infections following melarsoprol therapy. Molecular and Biochemical Parasitology 117 73 81
16. BarrettMP
FairlambAH
1999 The biochemical basis of arsenical-diamidine crossresistance in African trypanosomes. Parasitology Today 15 136 140
17. SnyderC
CholletJ
Santo-TomasJ
ScheurerC
WittlinS
2007 In vitro and in vivo interaction of synthetic peroxide RBx11160 (OZ277) with piperaquine in Plasmodium models. Experimental Parasitology 115 296 300
18. FarooqU
MahajanRC
2004 Drug resistance in malaria. Journal of Vector Borne Diseases 41 45 53
19. BacchiCJ
1993 Resistance to clinical drugs in African trypanosomes. Parasitol Today 9 190 193
20. BridgesDJ
GouldMK
NerimaB
MaserP
BurchmoreRJS
2007 Loss of the high-affinity pentamidine transporter is responsible for high levels of cross-resistance between arsenical and diamidine drugs in African trypanosomes. Molecular Pharmacology 71 1098 1108
21. LanteriCA
StewartML
BrockJM
AlibuVP
MeshnickSR
2006 Roles for the Trypanosoma brucei P2 transporter in DB75 uptake and resistance. Molecular Pharmacology 70 1585 1592
22. JacksonAP
2007 Origins of amino acid transporter loci in trypanosomatid parasites. BMC Evolutionary Biology 7 26
23. AlsfordS
HornD
2008 Single-locus targeting constructs for reliable regulated RNAi and transgene expression in Trypanosoma brucei. Molecular and Biochemical Parasitology 161 76 79
24. BiebingerS
WirtzLE
LorenzP
ClaytonC
1997 Vectors for inducible expression of toxic gene products in bloodstream and procyclic Trypanosoma brucei. Molecular and Biochemical Parasitology 85 99 112
25. Shaked-MishanP
Suter-GrotemeyerM
Yoel-AlmagorT
HollandN
ZilbersteinD
2006 A novel high-affinity arginine transporter from the human parasitic protozoan Leishmania donovani. Mol Microbiol 60 30 38
26. CanepaGE
SilberAM
BouvierLA
PereiraCA
2004 Biochemical characterization of a low-affinity arginine permease from the parasite Trypanosoma cruzi. FEMS Microbiol Lett 236 79 84
27. HasneMP
UllmanB
2005 Identification and characterization of a polyamine permease from the protozoan parasite Leishmania major. J Biol Chem 280 15188 15194
28. HasneMP
CoppensI
SoysaR
UllmanB
2010 A high-affinity putrescine-cadaverine transporter from Trypanosoma cruzi. Mol Microbiol 76 78 91
29. BacchiCJ
GarofaloJ
CiminelliM
RattendiD
GoldbergB
1993 Resistance to dl-alpha-difluoromethylornithine by clinical isolates of Trypanosoma brucei rhodesiense - role of S-adenosylmethionine. Biochemical Pharmacology 46 471 481
30. BacchiCJ
NathanHC
LivingstonT
ValladaresG
SaricM
1990 Differential susceptibility to dl-alpha-difluoromethylornithine in clinical isolates of Trypanosoma brucei rhodesiense. Antimicrobial Agents and Chemotherapy 34 1183 1188
31. BurkardGS
JutziP
RoditiI
2010 Genome-wide RNAi screens in bloodstream form trypanosomes identify drug transporters. Mol Biochem Parasitol
32. SokolovaAY
WyllieS
PattersonS
OzaSL
ReadKD
2010 Cross-resistance to nitro-drugs and implications for the treatment of human African trypanosomiasis. Antimicrobial Agents and Chemotherapy
33. JanssensPG
De MuynckA
1977 Clinical trials with “nifurtimox” in African trypanosomiasis. Annales de la Société belge de médecine tropicale 57 475 480
34. HirumiH
DoyleJJ
HirumiK
1977 Cultivation of bloodstream Trypanosoma brucei. Bulletin of the World Health Organization 55 405 409
35. RazB
ItenM
Grether-BuhlerY
KaminskyR
BrunR
1997 The Alamar Blue assay to determine drug sensitivity of African trypanosomes (T.b. rhodesiense and T.b. gambiense) in vitro. Acta Tropica 68 139 147
36. SambrookJ
RussellDW
2001 Preparation and Analysis of Eukaryotic Genomic DNA. Molecular cloning New York Cold Spring Harbor Laboratory Press 6.39 6.58
37. KamlehA
BarrettMP
WildridgeD
BurchmoreRJ
ScheltemaRA
2008 Metabolomic profiling using Orbitrap Fourier transform mass spectrometry with hydrophilic interaction chromatography: a method with wide applicability to analysis of biomolecules. Rapid Communications in Mass Spectrometry 22 1912 1918
Štítky
Hygiena a epidemiológia Infekčné lekárstvo LaboratóriumČlánok vyšiel v časopise
PLOS Pathogens
2010 Číslo 11
- Parazitičtí červi v terapii Crohnovy choroby a dalších zánětlivých autoimunitních onemocnění
- Očkování proti virové hemoragické horečce Ebola experimentální vakcínou rVSVDG-ZEBOV-GP
- Koronavirus hýbe světem: Víte jak se chránit a jak postupovat v případě podezření?
Najčítanejšie v tomto čísle
- Zn Inhibits Coronavirus and Arterivirus RNA Polymerase Activity and Zinc Ionophores Block the Replication of These Viruses in Cell Culture
- The Female Lower Genital Tract Is a Privileged Compartment with IL-10 Producing Dendritic Cells and Poor Th1 Immunity following Infection
- Crystal Structure and Size-Dependent Neutralization Properties of HK20, a Human Monoclonal Antibody Binding to the Highly Conserved Heptad Repeat 1 of gp41
- The Arabidopsis Resistance-Like Gene Is Activated by Mutations in and Contributes to Resistance to the Bacterial Effector AvrRps4